For instance, GSK126, despite its strong preclinical activity against mutant EZH2, failed to show meaningful clinical responses in a phase I trial in R/R DLBCL, transformed FL, and other NHL, leading to early trial termination [139,140]. Here, EZH2 is linked to diffuse large B-cell lymphoma.